AmeriPharma’s premier pharmacy services are available in multiple states throughout the US.
Mon - Fri: 9:00AM - 10:00PM Sat - Sun: Closed

Related Posts

Welcome to Infusion Center

Get Financial Relief Now

Apply for Kanjinti Copay Assistance

Free service matches you with top copay assistance programs

Specialists assist you throughout the application process

Get automated updates on your funding status

Over $55 million secured for our patients to date

How Much Can You Save?

Speak With a Copay Assistance Specialist

We accept Medicare, multi-state Medicaid, Medi-Cal, Blue Shield, and most private insurances.

Medi-Cal logo
LegitScript approved

Get Started in Minutes

How Kanjinti Copay Assistance Works

plus icon with transparent background

1 – Check Your Coverage/Benefits Verification

Our team of expert billers finds the best avenues of coverage that minimize out-of-pocket costs.

Rx icon

2 – Transfer Prescription to AmeriPharma

We process your prescription by working with your previous pharmacy or prescriber, making the transition quick and easy.

document icon with transparent background

3 – Prior Authorization

Our team of specialists obtains approval from your insurance companies within 24 to 72 hours.

document and personnel icon with transparent background

4 – Copay Assistance & Financial Aid

We secure financial aid and decrease copays, out-of-pocket expenses, and high deductibles. To date, AmeriPharma Specialty Care has secured $55 million in financial assistance for our patients.

3 hands and plus icon with transparent background

5 – Nursing Care Coordination

AmeriPharma puts your schedule and home environment first when scheduling and coordinating one of our specialized nurses for your in-home infusions.

box icon with transparent background

6 – Delivery Coordination

Medications are always delivered in strict compliance with the specific requirements for immune globulin shipping. Next-day and overnight cold-chain deliveries are coordinated around your schedule.

Speak With a Specialist

We accept Medicare, multi-state Medicaid, Medi-Cal, Blue Shield, and most private insurances. Call us to find out more about your coverage.

What Is Kanjinti?

Kanjinti was first approved by the FDA in 2019 as a biosimilar of an already-marketed anticancer drug called Herceptin. It is classified under the pharmacologic category of antineoplastic, monoclonal antibodies, and anti-HER2 drug agents. The active substance of Kajinti is “trastuzumab-anns.”

This medication is intended to slow the growth of HER2 overexpressing metastatic gastric cancer and breast cancers (early and metastatic) in adults. HER2 cancers typically begin when the HER2 proteins grow and divide in an uncontrollable way leading to an overexpression of these proteins. 

Schedule a Consultation

We accept Medicare, multi-state Medicaid, Medi-Cal, Blue Shield, and most private insurances. Call us to find out more about your coverage.

What Is Kanjinti Used To Treat?

Kanjinti has been approved for the labeled indications of metastatic gastric or gastroesophageal junction adenocarcinoma cancer, as well as breast cancer (both early and metastatic forms). 

Kanjinti may be prescribed under the following conditions:

  • In early breast cancer (where the cancer is localized within the breast and does not spread beyond the breast or lymph nodes to the other body parts). Kanjinti may be initiated after surgery, chemotherapy, and radiotherapy. It can be used as a single agent (if a patient has previously received chemotherapy) or combined with other chemotherapy drugs such as paclitaxel or docetaxel
  • In metastatic breast cancer (where the tumor has spread to other body parts), Kanjinti may be used alone if no other treatment has been shown to be effective. It can also be used in patients who have received one or more chemotherapy sessions. If patients have not received chemotherapy or any other therapy before, Kanjinti is used in combination with chemotherapy medicines (e.g.,  paclitaxel).
  • In metastatic gastric (stomach) cancer, Kanjinti can be used alone or in combination with other chemotherapy drugs (cisplatin and capecitabine), especially in patients who have not received any prior treatment.

Copay and Financial Assistance

AmeriPharma Specialty Care alleviates financial burdens for patients and their families

Advanced software icon
Advanced software locates funding sources to match you with top-dollar foundation programs
Copay assistance icon
One of our copay assistance specialists will assist with the application process
Funding status icon
Automatic updates will be sent to you and your physician on the status of the funding

Speak With a Specialist

We accept Medicare, multi-state Medicaid, Medi-Cal, Blue Shield, and most private insurances. Call us to find out more about your coverage.

Kanjinti Side Effects

Listed below are some of the common adverse side effects patients may experience during or after receiving an infusion of Kanjinti. 

In metastatic breast cancer settings, the most common side effects experienced by 10% or more  of the patients include: 

  • Fever, chills, and cough
  • Congestive heart failure
  • Infections, headache, fatigue
  • Vomiting and diarrhea
  • Rash 

In metastatic gastric cancer settings, the most common side effects experienced by 10% or more of the patients include: 

  • Neutropenia, anemia
  • Fever, diarrhea, weight loss
  • Stomatitis
  • Upper respiratory tract infections
  • Low platelet count (thrombocytopenia) 
  • Changes in taste (dysgeusia)
  • Mucosal inflammation
  • Nasopharyngitis 

In severe and adverse cases, the following may occur: 

  • Pulmonary toxicity (damage to lungs)
  • Embryo-fetal toxicity (usually occurs in patients who are pregnant and receiving Kanjinti infusion)
  • Cardiomyopathy
  • Chemotherapy-induced neutropenia exacerbation

Schedule a Consultation

We accept Medicare, multi-state Medicaid, Medi-Cal, Blue Shield, and most private insurances. Call us to find out more about your coverage.

Kanjinti Dosage and Schedule

The dosage of Kanjinti is different for gastric cancer and breast cancer (both early and metastatic). The doses of Kanjinti are adjusted in these patients according to the following criteria:

  • Patient’s body weight
  • Expression of HER2 proteins
  • Treatment plan: Will Kanjinti be given alone or in combination with adjuvant treatment (such as chemotherapy)? 
  • Treatment frequency: Will  Kanjinti be given once weekly or once every three weeks?

Dosage for Early Breast Cancer

The recommended initial dose of Kanjinti for patients with early breast cancer who are also receiving chemotherapy is 4 mg/kg given intravenously for 90 minutes. 

  • Initial dose: If the first dose is well tolerated, then the IV infusion time is shortened to 30 minutes with a subsequent dose of 2 mg/kg weekly during chemotherapy for the first 12 weeks (for patients taking docetaxel or paclitaxel) or 18 weeks (for patients taking carboplatin and docetaxel). 
  • Patients usually complete a total of 52 weeks of therapy.

Dosage for Metastatic Breast Cancer

The initial dose of Kanjinti alone or in combination with paclitaxel is 4 mg/kg for 90 minutes of IV infusion, followed by the subsequent dose of 2 mg/kg every week for 30 minutes until disease progression.

Dosage for Metastatic Gastric Cancer

The starting dose of Kanjinti alone is 8 mg/kg over 90 minutes, followed by the subsequent dose of 6 mg/kg every 3 weeks for over 30 to 90 minutes until disease progression.

How Much Can You Save?

Speak With a Copay Assistance Specialist

© 2024 AmeriPharma Specialty Care. All Rights Reserved.  132 S. Anita Dr. 2nd Floor, Orange, CA 92868. Privacy Policy | Terms of use